WO2021221447A1 - 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 - Google Patents
암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 Download PDFInfo
- Publication number
- WO2021221447A1 WO2021221447A1 PCT/KR2021/005341 KR2021005341W WO2021221447A1 WO 2021221447 A1 WO2021221447 A1 WO 2021221447A1 KR 2021005341 W KR2021005341 W KR 2021005341W WO 2021221447 A1 WO2021221447 A1 WO 2021221447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- androgen receptor
- oil
- oligonucleotide
- seq
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 86
- 201000011510 cancer Diseases 0.000 title claims abstract description 71
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 229940123407 Androgen receptor antagonist Drugs 0.000 title abstract description 8
- 239000003936 androgen receptor antagonist Substances 0.000 title abstract description 8
- 108010080146 androgen receptors Proteins 0.000 claims abstract description 99
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 77
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 40
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 40
- 102000001307 androgen receptors Human genes 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 108091027981 Response element Proteins 0.000 claims abstract description 4
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 41
- 125000003729 nucleotide group Chemical group 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 35
- 238000001890 transfection Methods 0.000 claims description 34
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 33
- 239000008158 vegetable oil Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 239000000944 linseed oil Substances 0.000 claims description 22
- 235000021388 linseed oil Nutrition 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 18
- 230000019491 signal transduction Effects 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000002103 transcriptional effect Effects 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 240000001890 Ribes hudsonianum Species 0.000 claims description 3
- 235000016954 Ribes hudsonianum Nutrition 0.000 claims description 3
- 235000001466 Ribes nigrum Nutrition 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 239000010460 hemp oil Substances 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims description 2
- 244000124853 Perilla frutescens Species 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 235000021324 borage oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000003098 androgen Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- 230000011664 signaling Effects 0.000 abstract description 13
- 230000005907 cancer growth Effects 0.000 abstract description 12
- 238000001415 gene therapy Methods 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 2
- 238000013518 transcription Methods 0.000 abstract description 2
- 230000035897 transcription Effects 0.000 abstract description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 94
- 102100032187 Androgen receptor Human genes 0.000 description 64
- 102000001301 EGF receptor Human genes 0.000 description 36
- 108060006698 EGF receptor Proteins 0.000 description 36
- 210000001519 tissue Anatomy 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 102000011931 Nucleoproteins Human genes 0.000 description 11
- 108010061100 Nucleoproteins Proteins 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000001114 immunoprecipitation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 102000005969 steroid hormone receptors Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108020003113 steroid hormone receptors Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100038595 Estrogen receptor Human genes 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- -1 cationic phospholipid Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002261 Androgen deficiency Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229940094199 black currant oil Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
- 229960004671 enzalutamide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to the use of an active androgen receptor antagonist for the treatment of cancer, and more specifically, as an active androgen receptor antagonist for the treatment of cancer, to the androgen receptor and signal protein complex formed by the interaction between androgen receptor and signal factor to the use of the oligonucleotide KilGreene to form a functional double strand.
- Androgen receptor belongs to the steroid receptor group, and has a function as a transcription factor.
- a steroid such as androgen
- LBD ligand binding domain
- the androgen receptor is separated from Hsp90 and migrated to the nucleus.
- the androgen receptor migrated into the nucleus binds to the androgen-responsive element (ARE) in the promoter and activates the transcription of the gene.
- ARE androgen-responsive element
- Prostate cancer the most common oncological disease in men and the second leading cause of cancer-related death in men, is mainly caused by the differentiation of luminal epithelial cells of the prostate, and androgen receptors are known to be involved in the differentiation of luminal epithelial cells of the prostate. . Androgen receptors control cell survival through mechanisms that have not yet been clearly defined. It has also been implicated in the pathogenesis of other cancers, including breast cancer, in addition to prostate cancer (Cato, A.C., et al. 1998. Trends Endocrinol Metab 9:150-154).
- Cancerous prostate cells continue to express androgen receptors. The survival of these cells also depends on the presence of androgens, which makes androgen deficiency the treatment of choice for patients with advanced prostate cancer.
- Anti-androgen treatment methods using, for example, the inhibitors flutamide and Casodex are generally effective initially, but complete cure is rare. Prostate cancer recurs in most patients treated with this treatment method, leading to androgen-independent, chemotherapy-resistant tumors with a poor prognosis.
- Androgen-independent prostate cancer is usually characterized by increased androgen receptor activity due to activation of receptor tyrosine kinase or expression of androgen receptor mutations responsive to non-androgen ligands (Chen, Y., et al. 2008. Curr Opin Pharmacol 8:440-448).
- androgen receptors are both androgen-dependent and androgen-independent cancers, and other androgen receptor positive cancer types such as "triple negative" (ER-, PR-, Her2-) breast cancer , represent a promising potential therapeutic target for bladder cancer and salivary gland cancer.
- the androgen receptor antagonists enzalutamide and bicalutamide are being used to treat prostate cancer (Minyong Kang and Ja Hyeon Ku. 2017, Translational Cancer Research 6(Suppl 4): S702-S707; P Li., et al. 2017. Cancers (Basel) 9(2): E20; Khoo., et al. 2017. Oncotarget 5(44): 75893-75903; CM Chiu., et al. 2007.
- androgen receptor antagonists inhibit the stimulation of cancer cells by disrupting or reducing the function of androgen receptors, including androgen receptor binding, transcriptional activity of androgen receptors, or cell transport of androgen receptors such as translocation from the cytoplasm to the nucleus. It is expected to be reduced.
- the current treatment modality is quite ineffective for androgen receptor-positive cancer, and thus there is a steady demand for the development of new androgen receptor antagonists for the treatment of androgen receptor-positive cancer cells.
- non small cell lung cancer is a disease that accounts for an important cause of malignant tumor-related deaths worldwide, and accounts for 75 to 88% of lung cancers.
- EGFR Extramal Growth Factor Receptor
- chemotherapeutic agents In order to obtain more satisfactory results, it is necessary to find a therapeutic target other than EGFR.
- An androgen receptor has been proposed in such an attempt (Sean Brennan., et al. 2017. Cancer Res 77(13 Suppl); Abstract 4121).
- the present inventors have made efforts to develop a cancer therapeutic agent that can be used in androgen receptor-positive cancers including androgen-dependent cancer and androgen-independent cancer.
- the oligonucleotide KilGreene according to the present invention is an androgen receptor and interacts with the androgen receptor in non-small cell lung cancer cells. The effect of inhibiting the growth of cancer cells was confirmed by removing the complex of signal factors.
- the oligonucleotide KilGreene according to the present invention can be usefully used as a gene therapy for androgen receptor signaling-related cancer treatment.
- the interaction between the active androgen receptor and the signal protein has been recognized as a novel anticancer drug, and it is a small molecule that binds to the N-terminal site of the androgen receptor and is being attempted for the treatment of intractable prostate cancer.
- An object of the present invention is to block androgen receptor signaling, which is a step of EGFR tyrosine kinase signaling in non-small cell carcinoma, by eliminating the interaction between the signal protein and androgen receptor through the oligonucleotide KilGreene according to the present invention.
- the present invention contains an oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double strand as an active ingredient, It provides a pharmaceutical composition for preventing or treating cancer.
- nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide containing as an active ingredient a pharmaceutical composition for preventing or treating cancer .
- the present invention prevents cancer by administering to an individual an oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded or a composition containing the same as an active ingredient or a method of treatment.
- the present invention also relates to: a) a transfection preparation containing a vegetable oil;
- nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide by administering to the subject a composition containing as an active ingredient to prevent or treat cancer provides a way to
- the present invention provides an oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide or a composition containing the same as an active ingredient for preventing or treating cancer to provide.
- the present invention also relates to: a) a transfection preparation containing a vegetable oil;
- nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide as an active ingredient.
- the oligonucleotide according to the present invention has an effect of inhibiting the growth of cancer cells by binding to a complex of androgen receptors and signaling proteins interacting therewith in non-small cell lung cancer cells. More specifically, the oligonucleotide according to the present invention interacts with androgen receptors that have migrated into the nucleus through androgen-independent signaling by EGFR in EGFR Tyrosine Kinase-positive non-small cell lung cancer cells, and binds to androgen receptors and signal protein complexes, and androgen receptors Since it has an effect of inhibiting the growth of cancer cells by blocking the transcriptional activity of , it can be usefully used as a gene therapy for androgen receptor signaling-related cancer treatment.
- FIG. 1 is a diagram confirming the degree of cell death of each of six non-small cell lung cancer cell lines transfected with an oligonucleotide (KilGreene) prepared in an embodiment of the present invention:
- Figure 2 is a diagram confirming the action of a signal factor in the Kil sequence contained in KilGreene and nucleoproteins extracted from 6 types of non-small cell lung cancer cell lines through EMSA:
- Figure 3 is a diagram confirming the signal protein binding to the kil sequence in KilGreene and the androgen receptor binding to GRE by performing EMSA using a nuclear extract of the NCI-H1793 cell line and a reaction product of KilGreene:
- FIG. 4 is a diagram illustrating the removal of androgen receptors in the nuclear protein extracted from the NCI-H1793 cell line by immunoprecipitation, and confirming the removed androgen receptors:
- Figure 5a is a diagram confirming the change in tumor volume in the NCI-H1793 (KilGreene) transplanted mouse model transfected with the non-small cell lung cancer cell line NCI-H1793 (Control) or KilGreene.
- Figure 5b is a diagram confirming the change in tumor volume in the NCI-H520 (KilGreene) transplanted mouse model transfected with the non-small cell lung cancer cell line NCI-H520 (Control) or KilGreene.
- Figure 6 is a view confirming the stability in flaxseed oil (flaxseed oil) of KilGreene.
- FIG. 7 is a diagram illustrating intracellular beta-galactosidase expression after intracellular transfection of pCMB-LaZ beta galactosidase vector using flaxseed oil.
- FIG. 8 is a view confirming the expression of luciferase in the crude after intravenous administration of a mixture of flaxseed oil and luciferase plasmid to rats.
- FIG. 9 is a diagram confirming the transduction of KilGreene and the anticancer effect in lung tissue after intravenous administration of a mixture of flaxseed oil and KilGreene to an animal model inducing lung cancer.
- 10 is a diagram schematically illustrating the mechanism of action of KilGreene.
- the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising an oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double strand as an active ingredient do.
- the oligonucleotide used in the present invention is a functional equivalent of a nucleic acid molecule constituting it, for example, even if some nucleotide sequences of the oligonucleotide are modified by deletion, substitution, or insertion, the oligonucleotide can have a functionally equivalent function. It is a concept that includes variants.
- the oligonucleotide of the present invention may exhibit 80% or more homology with the nucleotide sequence of each corresponding SEQ ID NO: Specifically, it may include 90% or more, more specifically, 95% or more homology.
- the oligonucleotide of the present invention is 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more may include indicating.
- Such homology can be readily determined by comparing the sequence of the nucleotides to the corresponding portion of the target gene using computer algorithms well known in the art, for example, the Align or BLAST algorithm.
- oligonucleotides used in the present invention can be isolated or prepared using standard molecular biology techniques, for example, chemical synthesis methods or recombinant methods.
- the oligonucleotide may be provided in a form captured by a carrier for introduction into a cell.
- the carrier may be, for example, G-fectin, Mirus TrasIT-TKO lipophilic reagent, lipofectin, lipofectamine, cellfectin, cationic phospholipid nanoparticles, cationic polymer, cationic micelles, cationic emulsion or Liposomes may be mentioned, but are not limited thereto, and may be used without limitation as long as they function as a carrier.
- a biocompatible polymer such as polyethylene glycol
- vegetable oil containing a large amount of unsaturated fatty acids such as linolenic acid, linoleic acid and oleic acid is used as a carrier for introducing the oligonucleotide according to the present invention into a cell. It was confirmed that it is possible.
- the unsaturated fatty acid changes the structure of the cell membrane to increase permeability and fluidity. These changes change the activity of receptors in the cell membrane of cancer cells, thereby facilitating the intracellular introduction of anticancer agents.
- the oligonucleotide is an upstream (-204) to (-188) site based on the transcription start site (+1) of the mouse mammary tumor virus (MMTV) promoter gene.
- MMTV mouse mammary tumor virus
- the oligonucleotide includes upstream (-186) to (-170) sites based on the transcription start site (+1) of the mouse mammary tumor virus promoter gene.
- the upstream (-204) to (-188) region based on the transcription start site (+1) of the mouse mammary tumor virus promoter gene is known as the Kil sequence or Kil site, and the upstream ( The regions -186) to (-170) are known as distal glucocorticoid response elements (GREs).
- the Kil sequence is known as an enhancer that acts on steroid hormone receptors that act on the distal GRE, such as glucocorticoid receptor (GR), progesterone receptor (PR), and estrogen receptor (ER) (EMBO Genebank x16475).
- GR glucocorticoid receptor
- PR progesterone receptor
- ER estrogen receptor
- the oligonucleotide binds to a steroid hormone receptor, specifically an androgen receptor and a signal factor interacting therewith, in the nucleus including the Kil sequence and the distal GRE. More specifically, the oligonucleotide binds to the androgen receptor and signal protein complex formed by the interaction between the activated androgen receptor and the signal protein, wherein the activated androgen receptor binds to the distal GRE, and the signal protein binds to the Kil sequence .
- the androgen receptor is activated by several signaling pathways. For example, it is known that in some cancers androgen receptors are activated through two signaling pathways, specifically androgen-dependence signaling pathway and androgen-independence signaling pathway, to promote the growth of cancer cells. .
- the androgen-dependent signaling pathway is a signaling pathway in which androgen receptors are activated by binding of androgen receptors with dihydrotestosterone produced by conversion of androgens by 5 ⁇ -reductase in cells.
- the androgen-independent signaling pathway is a signaling pathway in which PI3K is activated by phosphorylation of receptor tyrosine kinase such as EGFR, and thereby Akt is activated to activate the androgen receptor.
- Activated androgen receptors bind to signal proteins, such as androgen receptor elements, in the nucleus to promote gene expression (L. Gerratana., et al. 2018. Cancer treatment reviews 68: 102-110).
- the oligonucleotide binds to a complex of an androgen receptor activated through an androgen-dependent or androgen-independent signaling pathway and a signal protein interacting therewith, thereby inhibiting the transcriptional activity of the androgen receptor. More specifically, the oligonucleotide inhibits the transcriptional activity of the androgen receptor, thereby inhibiting cancer cell growth.
- the cancer is preferably androgen receptor-positive cancer.
- the cancer may include, but is not limited to, non-small cell lung cancer, bladder cancer, breast cancer, liver cancer, prostate cancer, colorectal cancer, thyroid cancer, salivary gland cancer, glioblastoma or astrocytoma.
- the cancer may include androgen receptor-positive non-small cell lung cancer, bladder cancer, breast cancer, liver cancer, prostate cancer, colorectal cancer, thyroid cancer, salivary gland cancer, glioblastoma or astrocytoma, but is not limited thereto.
- the present inventors prepared an oligonucleotide according to the present invention using the MMTV promoter region, and named it "KilGreene”.
- NSLC Non Small Lung Cancer
- KilGreene binds to a complex of androgen receptor in the nucleus of an apoptosis-induced EGFR-positive non-small cell lung cancer cell line and a signal protein that interacts therewith, and specifically, EGFR-positive at the GRE site distal to KilGreene. It was confirmed that the activated androgen receptor in the nucleus of the non-small cell lung cancer cell line binds to the Kil sequence region and a signal protein interacting with the activated androgen receptor binds to inhibit the transcriptional activity of the androgen receptor, thereby inducing apoptosis.
- cancer cell growth occurs by transcriptional action from EGFR in the cell membrane of EGFR-positive non-small cell lung cancer cells through the signaling pathway between the nuclear signal protein and the androgen receptor. It was confirmed that the cross-talking of the tyrosine kinase EGFR, which instructs the existing cell growth, was blocked.
- the present inventors confirmed the effect that the oligonucleotide according to the present invention inhibits the growth of cancer cells by binding to androgen receptors activated in the nucleus and signaling proteins interacting therewith through the androgen-independent signaling pathway by EGFR in cancer cells.
- the oligonucleotide according to the present invention can be usefully used as an active ingredient in a pharmaceutical composition for androgen receptor signaling-related cancer treatment as a gene therapy agent.
- composition of the present invention may further comprise a pharmaceutically acceptable carrier, and may be formulated together with the carrier.
- the pharmaceutically acceptable carrier refers to a carrier or diluent that does not stimulate the organism and does not inhibit the biological activity and properties of the administered compound.
- acceptable pharmaceutical carriers for compositions formulated as liquid solutions include sterile and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection, dextrose solution, maltodextrin solution, Glycerol, ethanol, and one or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostats may be added as needed. It may also be formulated as a solution or suspension (eg, integrated with microparticles, liposomes, or cells).
- composition of the present invention may be applied to any formulation containing it as an active ingredient, and may be prepared and administered as an oral or parenteral formulation.
- Administration means introducing a composition of the present invention to a patient by any suitable method, including transplantation of cells expressing a nucleic acid molecule.
- the administration route of the composition of the present invention may be administered through various routes, either oral or parenteral, as long as it can reach the target tissue.
- oral administration, transdermal administration, topical administration, inhalation administration, intrapulmonary administration, intrathecal administration, intranasal administration, intravenous administration, intramuscular administration, intradermal administration, intraperitoneal administration or subcutaneous administration may be made, but Not limited.
- composition and treatment method of the present invention are applicable to any animal capable of developing cancer, and the animal includes not only humans and primates, but also domestic animals such as cattle, pigs, sheep, horses, dogs and cats.
- the effective amount of the composition of the present invention or a suitable total daily amount can be determined by a treating physician within the scope of sound medical judgment.
- a specific therapeutically effective amount for a particular patient will depend on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the patient's age, weight, general health, sex and diet, time of administration; It is preferable to apply differently depending on various factors including the route of administration and secretion rate of the composition, treatment period, and radiation dose to be irradiated and similar factors well known in the pharmaceutical field. For example, it may be used at 0.001 ⁇ g/kg-100 mg/kg (body weight) per day, but is not limited thereto.
- the effective amount of the pharmaceutical composition suitable for the purpose of the present invention is preferably determined in consideration of the foregoing.
- the present invention also provides a transfection preparation comprising a vegetable oil.
- the vegetable oil is flaxseed oil, corn oil, borage oil, safflower oil, soybean oil, perilla oil, evening primrose oil, sunflower oil, blackcurrant oil (blackcurrant pip oil), malt oil (wheatgerm oil), hemp oil (hemp oil) or squash seed oil (marrow seed oil) may be, specifically, may be flaxseed oil, but is not limited thereto.
- the vegetable oil may contain 70 to 99% by weight (w/w) of C 18 fatty acids based on the total weight of the oil , and examples of the C 18 fatty acids include linolenic acid, linoleic acid ) and oleic acid, but is not limited thereto.
- the transfection agent can be used for in vitro or in vivo transfection through the following steps:
- the transfection agent: oligonucleotide may be mixed in a weight ratio of 1 to 5: 1, specifically, may be mixed in a weight ratio of 1 to 3 : 1, and more specifically, 1 to 2 : 1 by weight. may be mixed, but is not limited thereto.
- the stirring in step 1) may be specifically performed for 30 seconds to 120 seconds, more specifically 50 seconds to 90 seconds using a vortex device, but is not limited thereto.
- the mixture in step 2) may be carried out for 30 seconds to 120 seconds, more specifically 50 seconds to 90 seconds, but is not limited thereto.
- the present inventors confirmed that the oligonucleotide including the oligonucleotide according to the present invention was transfected into cells and tissues using flaxseed oil as a vegetable oil harmless to the human body, thereby exhibiting excellent transfection efficiency.
- the present inventors confirmed that vegetable oil harmless to the human body can be used as a vehicle for in vitro or in vivo introduction of the oligonucleotide containing the oligonucleotide according to the present invention, so that the vegetable oil containing the oligonucleotide according to the present invention can be used. It can be usefully used as an active ingredient of a transfection agent for transfection of oligonucleotides in vitro or in vivo.
- composition for preventing or treating cancer, containing as an active ingredient.
- the types of the oligonucleotides and cancer are the same as those described in the pharmaceutical composition for preventing or treating cancer, containing the oligonucleotide as an active ingredient, and therefore, the detailed description will refer to the above contents and hereinafter, vegetable oils and oligonucleotides Only the specific composition of the pharmaceutical composition for preventing or treating cancer containing nucleotides as an active ingredient will be described.
- the pharmaceutical composition may be administered orally or parenterally.
- oral administration, transdermal administration, topical administration, inhalation administration, intrapulmonary administration, intrathecal administration, intranasal administration, intravenous administration, intramuscular administration, intradermal administration or intraperitoneal administration may be administered.
- inhalation it is possible to increase the efficiency of delivery of oligonucleotides to lung tissue.
- the present inventors can introduce the oligonucleotide according to the present invention into cells and tissues using flaxseed oil as a vegetable oil harmless to the human body, and the present invention introduced into lung tissue using flaxseed oil It was confirmed that the oligonucleotide according to the present invention exhibits excellent anticancer effect.
- the present inventors have confirmed that vegetable oil harmless to the human body can be used as a carrier for introducing the oligonucleotide according to the present invention into cells, so the oligonucleotide and vegetable oil according to the present invention can be used as a pharmaceutical for androgen receptor signaling-related cancer treatment. It can be usefully used as an active ingredient in the composition.
- the oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide or a composition containing the same as an active ingredient is administered to an individual to treat cancer
- a method of preventing or treating is provided.
- the subject refers to any animal, including humans, that has already or can develop a disease that can be prevented or treated through anticancer activity, and cancer disease by administering the oligonucleotide according to the present invention, or a composition containing the same, to the subject. can be effectively prevented and treated.
- the present invention also relates to: a) a transfection preparation containing a vegetable oil;
- nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide by administering to the subject a composition containing as an active ingredient to prevent or treat cancer provides a way to
- the present invention provides an oligonucleotide in which the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide or a composition containing the same as an active ingredient for preventing or treating cancer to provide.
- the present invention also relates to: a) a transfection preparation containing a vegetable oil;
- nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 2 are complementary to each other to form a double-stranded oligonucleotide as an active ingredient.
- treatment includes a partial cure, improvement and alleviation of cancer symptoms, as well as cure of cancer diseases as a result of applying the pharmaceutical composition of the present invention to cancer diseases, growth of cancer or metastasis to other organs, or cancer symptoms.
- prevention means to prevent cancer from occurring in advance by applying the pharmaceutical composition of the present invention to inhibit or block the occurrence, growth, or metastasis of cancer to other organs.
- active ingredient refers to a component that exhibits activity alone or together with a carrier that is not active by itself.
- the oligonucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 1 (5'-AGCTTCCCAGGGTTTAAATAAGTTTAATGGTTACAAACTGTTCTTAAAACGCT-3') and the nucleotide sequence represented by SEQ ID NO: 2 (5'-AGGGTCCCAAATTTATTCAAATTACCAATGTTTGACAAGAATTTTGCGAGATC-3') Bioneer, Korea) was commissioned and synthesized.
- each of the synthesized oligonucleotides was mixed in equal amounts, heated at 100° C., and then slowly left at room temperature, so that the oligonucleotide of SEQ ID NO: 1 and the oligonucleotide of SEQ ID NO: 2 complementarily bind to each other to form a double strand. did. Thereafter, the double-stranded oligonucleotide was separated on a 7% SDS PAGE gel. In addition, the double-stranded oligonucleotide prepared above was named "KilGreene".
- KilGreene is a Kil sequence (Kil sequence or Kil site) known as the mouse mammary tumor virus (MMTV) promoter (promoter) gene transcription start site (+1) upstream (upstream) -204 to -188 site (SEQ ID NO: 3: 5'-GGGTTTAAATAAGTTTA-3') and -186 to -170 site (SEQ ID NO: 4: 5'-GGTTACAAACTGTTCT-3') known as distal glucocorticoid response element (GRE).
- MMTV mouse mammary tumor virus
- EGFR-positive epidermal growth factor receptor (EGFR)-positive Non Small Lung Cancer (NSCLC) various types of EGFR-positive or negative non-small cell lung cancer cells were treated with KilGreene and MTT (3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was analyzed to determine the degree of cell death.
- MTT 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- NCl-H596, Calu-3, SK-LU-1, SK-MES-1 and NCl-H1793, known as EGFR-positive non-small cell lung cancer cell lines, and NCI-H520, known as EGFR-negative non-small cell lung cancer cell lines, were used in the U.S. Cell Line Bank. (American tissue and cell collection) using 10% FBS-MEM medium or 10% FBS-RPMI1640 medium 5% CO 2 , cultured at 37 °C. Then, each of the cells was inoculated in a 60 mm culture dish with a number of 1 ⁇ 10 5 cells, and then 10 ⁇ l of 100 ⁇ g of KilGreene prepared in Example 1 was added to 10 ⁇ l of lipofectamine (Thermo Fisher Scientific). After transfection according to the manufacturer's procedure, cultured for 3 weeks.
- FIG. 1 it was confirmed that a remarkably high apoptosis was observed in the case of EGFR-positive non-small cell lung cancer cell lines treated with KilGreene except for SK-MES-1.
- apoptosis was insufficient.
- the Kil sequence in KilGreene is known to act as a regulatory protein of steroid hormone receptors.
- EMSA epidermal growth factor receptor
- nucleoproteins were extracted from NCl-H596, Calu-3, SK-LU-1, NCl-H1793, SK-MES-1 and NCI-H520 of 1x10 9 cells.
- the following solutions were used as nucleoprotein solutions: Buffer A (10 mM Tris-HCl (pH 7.5), 2 mM MgCl 2 , 3 mM NaCl, 0.2 mM Nonidet p-40, 0.5 mM PMSF) , 2 ug/ml leupeptin, 2 ug/ml aprotinin, buffer B (10 mM Tris-HCl (pH 7.5), 0.5 mM DTT, 0.5 mM PMSF), buffer C (10 mM Tris- HCl (pH 7.5), 2 mM MgCl 2 , 0.5 mM DTT, 0.1 mM PMSF), buffer D (10 mM Tris-HCl (pH 7.5), 80 mM NaCl, 3 mM
- nucleoprotein was extracted from NCl-H1793 in 1x10 9 cells, an EGFR-positive non-small cell lung cancer cell line showing the best effect by KilGreene. .
- KilGreene prepared in ⁇ Example 1> KI Lee., et al. (JBC 1995 270(41): 24502-24508), [ ⁇ - 32 P]dCTP was labeled by the same method.
- immunoprecipitation was performed as follows. To 875 ul of the extracted nucleoprotein, 200 ug of rabbit anti-androgen receptor antibody (Sigma A4719) was added and reacted with stirring at 4° C. for 30 minutes. After the reaction, 100 ul of protein A-agarose beads were added and reacted in the same manner as above. After completion of the reaction, the beads and the supernatant were separated by centrifugation for 2 minutes.
- beads were recovered and immunoprecipitation buffer (1% Tritonx-100, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA (pH) 8.0), protease inhibitor), and centrifuged at 4° C. for 2 minutes to separate beads and wash solution, and each was recovered. 50 ul of 0.1 M glycine (glycine, pH 2.5) was added to the recovered beads and mixed, followed by reaction at 4° C. for 10 minutes while stirring. next. The supernatant was obtained by centrifugation at 4° C. for 2 minutes. The obtained supernatant (immunoprecipitation product) and the recovered washing solution were electrophoresed on a 7% SDS PAGE gel (FIG. 4).
- immunoprecipitation buffer 1% Tritonx-100, 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 m
- NCI-H1973, an EGFR-positive non-small cell lung cancer cell line showing the best effect by KilGreene, and NCI-H520, an EGFR-negative non-small cell lung cancer cell line with insufficient effect, were obtained with 2 ⁇ 10 6 cells. and 10 ⁇ l of 100 ⁇ g of KilGreene prepared in ⁇ Example 1> was transfected using 10 ⁇ l of Lipofectamine according to the manufacturer's procedure. Then, the KilGreene-transfected cells were injected subcutaneously into the lateral flank of 4-week-old BALB/C female nude mice obtained from Charles river Laboratories and given once a week for 6 weeks to measure the tumor volume using a caliper at the time. did. The tumor volume was calculated by measuring the length (a), width (b) and height (c) as follows: tumor volume tumor length (a) ⁇ tumor width (b) ⁇ tumor height (c)/2.
- KilGreene can be transfected intracellularly or into tissues using a plant oil that is harmless to the human body, flaxseed oil rich in linolenic acid, linoleic acid and oleic acid as a vegetable oil (flaxseed oil) oil), the stability of KilGreene was confirmed.
- flaxseed oil was used to determine the transfection efficiency of DNA in cells and tissues.
- NIH 3T3 cells were treated and transfected. At this time, NIH 3T3 cells were cultured in a culture medium from which BSA was removed one day before transfection was used. Then, using a beta-galactosidase staining kit (beta galactosidase staining kit, abcam) according to the manufacturer's procedure, beta-galactosidase analysis was performed (FIG. 7).
- F344/N rats were divided into a control group, a KilGreene untreated group and a KilGreene treated group, and in the KilGreene untreated group and KilGreene treated group, RR1022 cells, a rat sarcoma cell, were treated with 7 ⁇ 10 6 cells in PBS. After adding to 500 ul, it was injected into the tail vein to induce lung cancer for 7 days.
- the oligonucleotide according to the present invention has an effect of inhibiting the growth of cancer cells by binding to a complex of androgen receptor and a signal protein interacting therewith in non-small cell lung cancer cells. More specifically, the oligonucleotide according to the present invention is EGFR Tyrosine Kinase-positive In non-small cell lung cancer cells, through androgen-independent signaling by EGFR, it binds to the androgen receptor and signal protein complex formed by interaction with the androgen receptor that has migrated into the nucleus, and has the effect of inhibiting the growth of cancer cells by blocking the transcriptional activity of androgen receptors. , it can be usefully used as a gene therapy for androgen receptor signaling related cancer treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (18)
- 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드를 유효성분으로 함유하는, 암 예방 또는 치료용 약학 조성물.
- 제 1항에 있어서, 상기 올리고뉴클레오티드는 생쥐유방종양바이러스(Mouse mammary tumor virus; MMTV) 프로모터(promoter) 유전자의 전사 시작부위(+1)를 기준으로부터 업스트림(upstream) (-204) 내지 (-188) 부위(Kil 서열: Kil sequence) 및 업스트림 (-186) 내지 (-170) 부위(먼쪽 GRE: distal glucocorticoid response element)를 포함하는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 1항 또는 제 2항에 있어서, 상기 올리고뉴클레오티드는 활성화된 안드로겐 수용체 및 신호 단백질(signal factor) 간 상호작용으로 형성된 안드로겐 수용체 및 신호 단백질의 복합체와 결합하는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 3항에 있어서, 상기 활성화된 안드로겐 수용체는 먼쪽 GRE에 결합하고, 상기 신호 단백질은 Kil 서열에 결합하는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 1항에 있어서, 상기 올리고뉴클레오티드는 안드로겐 의존성(androgen-dependence) 또는 안드로겐 독립성(androgen-indepdence) 신호전달 경로를 통해 활성화된 안드로겐 수용체 및 신호 단백질의 복합체와 결합하여 활성화된 안드로겐 수용체의 전사 활성을 억제하는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 5항에 있어서, 상기 올리고뉴클레오티드는 안드로겐 수용체의 전사 활성을 억제하여 암세포 성장을 억제하는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 1항에 있어서, 상기 암은 안드로겐 수용체 양성 암인 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제 1항에 있어서, 상기 암은 비소세포폐암, 방광암, 유방암, 간암, 전립선암, 대장암, 갑상샘암, 침샘암, 교아세포종 및 성상 세포종으로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 식물성 오일을 함유하는 형질감염 제제.
- 제 9항에 있어서, 상기 식물성 오일은 아마씨 오일(flaxseed oil), 옥수수 오일, 보라고 오일(borage oil), 잇꽃 오일(safflower oil), 콩기름, 들기름, 달맞이꽃 오일(evening primrose oil), 해바라기 오일, 까막까치밥 오일(blackcurrant pip oil), 맥아 오일(wheatgerm oil), 삼 오일(hemp oil) 및 서양호박씨 오일(marrow seed oil)로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 형질감염 제제.
- 제 9항에 있어서, 상기 식물성 오일은 오일 총 중량 기준으로 C 18의 지방산을 70 내지 99중량% (w/w)로 포함하는 것을 특징으로 하는, 형질감염 제제.
- 제 11항에 있어서, 상기 C 18의 지방산은 리놀렌산(linolenic acid), 리놀레산(linoleic acid) 및 올레산(oleic acid)으로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 형질감염 제제.
- a) 제 9항 내지 제 12항 중 어느 한 항의 형질감염 제제; 및b) 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드를 유효성분으로 함유하는, 암 예방 또는 치료용 약학 조성물.
- 제 13항에 있어서, 상기 약학 조성물은 경구 투여, 경피 투여, 국소 투여, 흡입 투여, 폐내 투여, 경막 내 투여, 비강내 투여, 정맥내 투여, 근육 내 투여, 피내 투여, 복강내 투여로 이루어진 군으로부터 선택되는 어느 하나 이상의 투여 방법으로 투여되는 것을 특징으로 하는 약학적 조성물.
- 약학적으로 유효한 양의, 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드, 또는 이를 유효성분으로 함유하는 조성물을, 개체에 투여하는 단계를 포함하는, 암 예방 또는 치료방법.
- 약학적으로 유효한 양의, a) 식물성 오일을 함유하는 형질감염 제제; 및 b) 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드를 유효성분으로 함유하는 조성물을, 개체에 투여하는 단계를 포함하는, 암 예방 또는 치료방법.
- 암 예방 또는 치료용 약학적 조성물로 사용하기 위한, 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드의 용도.
- 암 예방 또는 치료용 약학적 조성물로 사용하기 위한, a) 식물성 오일을 함유하는 형질감염 제제; 및 b) 서열번호 1로 표시되는 염기서열과 서열번호 2로 표시되는 염기서열이 서로 상보적으로 결합하여 이중가닥을 형성하는 올리고뉴클레오티드를 유효성분으로 함유하는 조성물의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0051065 | 2020-04-27 | ||
KR1020200051065A KR102231066B1 (ko) | 2020-04-27 | 2020-04-27 | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021221447A1 true WO2021221447A1 (ko) | 2021-11-04 |
Family
ID=75223682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/005341 WO2021221447A1 (ko) | 2020-04-27 | 2021-04-27 | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102231066B1 (ko) |
WO (1) | WO2021221447A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102231066B1 (ko) * | 2020-04-27 | 2021-03-23 | 이경일 | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950703056A (ko) * | 1992-08-07 | 1995-08-23 | 티. 지. 팔코너 | 래트 프로바신 유전자의 dna서열에 의한 안드로겐 조절(androgen regulation with dna sequences of rat probasin gene) |
KR102231066B1 (ko) * | 2020-04-27 | 2021-03-23 | 이경일 | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 |
-
2020
- 2020-04-27 KR KR1020200051065A patent/KR102231066B1/ko active IP Right Grant
-
2021
- 2021-04-27 WO PCT/KR2021/005341 patent/WO2021221447A1/ko active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950703056A (ko) * | 1992-08-07 | 1995-08-23 | 티. 지. 팔코너 | 래트 프로바신 유전자의 dna서열에 의한 안드로겐 조절(androgen regulation with dna sequences of rat probasin gene) |
KR102231066B1 (ko) * | 2020-04-27 | 2021-03-23 | 이경일 | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 |
Non-Patent Citations (3)
Title |
---|
ANILMIS NUR MERVE, KARA GOKNUR, KILICAY EBRU, HAZER BAKI, DENKBAS EMIR BAKI: "Designing siRNA-conjugated plant oil-based nanoparticles for gene silencing and cancer therapy", JOURNAL OF MICROENCAPSULATION, vol. 36, no. 7, 3 October 2019 (2019-10-03), Taylor & Francis Ltd, pages 635 - 648, XP009531542, ISSN: 0265-2048, DOI: 10.1080/02652048.2019.1665117 * |
LEE KYONG-IL PREMKUMAR, E. PREMKUMAR REDDY, C. DAMODARA REDDY: "Cellular Factors Binding to a Novel cis-Acting Element Mediate Steroid Hormone Responsiveness of Mouse Mammary Tumor Virus Promoter*", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 41, 1 October 1995 (1995-10-01), pages 24502 - 24508, XP055863941, DOI: 10.1074/jbc.270.41.24502 * |
SONG J, CHO SJ, LEE KI, KIM SH, KANG JS, LEE KW, LEE JY, KU PS: "Suppression of Steroid Receptor Function by Retinoblastoma Protein in Breast Cancer Cell Line, MCF 7", KOREAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 40, no. 10, 1 October 1997 (1997-10-01), Korea, pages 2269 - 2278, XP009531544, ISSN: 0494-4755 * |
Also Published As
Publication number | Publication date |
---|---|
KR102231066B1 (ko) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010041913A9 (ko) | Grs 단백질 또는 이의 단편의 신규한 용도 | |
WO2014204281A9 (ko) | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 | |
WO2013137505A1 (ko) | 신규한 trpv1 억제 펩티드 및 이를 함유하는 피부노화 방지 또는 주름 개선용 조성물 | |
WO2021221447A1 (ko) | 암 치료를 위한 활성 안드로겐 수용체 길항제의 용도 | |
Pommier et al. | Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene | |
WO2021010723A1 (en) | Melanophilin antisense oligonucleotides | |
WO2015005670A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
WO2019117660A2 (ko) | Crispr 시스템 기능 향상 방법 및 그의 이용 | |
WO2022065919A1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물 | |
WO2015005669A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
WO2011049264A1 (ko) | 표적 마이크로 알엔에이의 생성을 촉진하는 양면성 펩타이드 및 이를 이용한 표적 마이크로 알엔에이 생성 조절 방법 | |
WO2019117662A2 (ko) | Tert 프로모터 돌연변이에 특이적인 crispr 시스템 및 그의 이용 | |
Xu et al. | Pituitary prolactin-secreting tumor formation: recent developments | |
WO2018155890A1 (ko) | 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA | |
WO2017007241A1 (ko) | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 | |
WO2021125762A1 (ko) | 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체를 유효성분으로 함유하는 치매 예방 또는 치료용 조성물 | |
WO2021002664A1 (ko) | 암의 예방, 개선 또는 치료용 조성물 | |
Doroszko et al. | Luteinizing hormone and GATA4 action in the adrenocortical tumorigenesis of gonadectomized female mice | |
WO2017061828A1 (ko) | Plrg1 (pleiotropic regulator 1) 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
WO2010095879A2 (ko) | 세포사멸 관련 유전자의 전사체에 결합하는 siRNA 및 이를 이용한 암 치료용 조성물 | |
WO2015111971A1 (ko) | Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 | |
WO2017164486A1 (ko) | Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법 | |
WO2023249439A1 (ko) | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 | |
WO2018056583A1 (ko) | Sh3bp4 억제 물질을 포함하는 피부 미백용 조성물 및 sh3bp4 억제 물질의 스크리닝 방법 | |
WO2023096351A1 (ko) | 상피세포성장인자수용체(egfr) 변이를 갖는 암 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21796165 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21796165 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/04/2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21796165 Country of ref document: EP Kind code of ref document: A1 |